title: Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma.
abstract: OBJECTIVE
  The effects of switching from topical beta-blockers (beta) to latanoprost (LA) on intraocular pressure (IOP) and IOP-reduction rate (IOP-RR) in patients with normal-tension glaucoma (NTG) were investigated.
  
  
  METHODS
  Sixty (60) NTG patients (60 eyes) were divided into three equal groups receiving carteolol hydrochloride (group A), nipradilol (group B), and betaxolol hydrochloride (group C) twice-daily for 3 months. The drugs were changed to topical LA administered once-daily for the next 3 months.
  
  
  RESULTS
  Baseline IOP was 14.4 +/- 0.9, 14.6 +/- 0.6, and 14.6 +/- 0.9 mmHg in groups A, B, and C, respectively. At 3 months, IOP was 12.4 +/- 0.6, 13.4 +/- 0.6, and 12.9 +/- 0.8 mmHg and 10.5 +/- 0.5, 11.1 +/- 0.8, and 11.7 +/- 0.8 mmHg at 6 months in groups A, B, and C, respectively. At 3 months, IOP-RR was 10.4 +/- 5.5, 9.5 +/- 2.6, and 10.8 +/- 4.7% and 24.1 +/- 4.3, 22.9 +/- 5.9, and 19.4 +/- 3.8% at 6 months in groups A, B, and C, respectively. The groups did not significantly differ in the first 3 months regarding IOP and IOP-RR. Switching to LA significantly decreased IOP and increased IOP-RR in all groups.
  
  
  CONCLUSIONS
  In NTG patients, LA reduced IOP more effectively than the beta tested.
authors.affiliation: Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan. yikeda@ophth.kpu-m.ac.jp
authors.forename: Yoko
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Mori
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ishibashi
authors.forename: Shigeta
authors.initials: S
authors.lastname: Naruse
authors.forename: Nobuko
authors.initials: N
authors.lastname: Nakajima
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kinoshita
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000494:pharmacology*; D015784:Betaxolol / Q000494:pharmacology; D002354:Carteolol / Q000494:pharmacology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011412:Propanolamines / Q000494:pharmacology; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011412:Propanolamines; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D002354:Carteolol; C036089:nipradilol; D015784:Betaxolol